Literature DB >> 9427722

A naturally occurring mutation in Fc gamma RIIA: a Q to K127 change confers unique IgG binding properties to the R131 allelic form of the receptor.

C F Norris1, L Pricop, S S Millard, S M Taylor, S Surrey, E Schwartz, J E Salmon, S E McKenzie.   

Abstract

Fc gamma RIIa is widely expressed on hematopoietic cells. There are two known allelic polymorphic forms of Fc gamma RIIa, Fc gamma RIIa-R131 and Fc gamma RIIa-H131, which differ in the amino acid at position 131 in the second lg-like domain. In contrast to Fc gamma RIIa-R131, Fc gamma RIIa-H131 binds hlgG2 but not mIgG1, and this differential binding has clinical implications for host defense, autoimmune disease, immunohematologic disease, and response to therapeutic monoclonal antibodies. We identified a novel Fc gamma RIIA genotype in a healthy individual homozygous for Fc gamma RIIA R/R131 in whom a C to A substitution at codon 127 changes glutamine (Q) to lysine (K) in one of the two Fc gamma RIIA genes. This individual's homozygosity for Fc gamma RIIA-R/R131 leads to the prediction that the receptors on her cells would not bind hIgG2. Monocyte and neutrophil phagocytosis of hIgG2-opsonized erythrocytes was significantly higher (P < .05) for cells from this K/Q127, R/R131 individual than for Q/Q127, R/R131 donors. Platelet aggregation stimulated by an mIgG1 anti-CD9 antibody in this individual was significantly different (P < .05) from Q/Q127, H/R131 and Q/Q127, H/H131 donors and similar to Q/Q127, R/R131. Our data show that the K127/R131 receptors have a unique phenotype, binding both hIgG2 and mIgG1. Further functionally significant mutations in human Fc gamma receptors and possible novel mechanisms for inherited differences in disease susceptibility should be sought with unbiased screening methods.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9427722

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

Review 1.  Functions of the Fc receptors for immunoglobulin G.

Authors:  B K Flesch; J Neppert
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

Review 2.  Diversity and duplicity: human FCgamma receptors in host defense and autoimmunity.

Authors:  Robert P Kimberly; Jianming Wu; Andrew W Gibson; Kaihong Su; Hongwe Qin; Xiaoli Li; Jeffrey C Edberg
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

3.  Fcγ receptor IIB (FcγRIIB) maintains humoral tolerance in the human immune system in vivo.

Authors:  Anne Baerenwaldt; Anja Lux; Heike Danzer; Bernd M Spriewald; Evelyn Ullrich; Gordon Heidkamp; Diana Dudziak; Falk Nimmerjahn
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-07       Impact factor: 11.205

4.  High immunoglobulin G2 (IgG2) and low IgG4 levels are associated with human resistance to Plasmodium falciparum malaria.

Authors:  C Aucan; Y Traoré; F Tall; B Nacro; T Traoré-Leroux; F Fumoux; P Rihet
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

Review 5.  FcgammaRII and multi-system autoimmune disease.

Authors:  Nicholas C van de Velde; Patricia L Mottram; P Mark Hogarth
Journal:  Springer Semin Immunopathol       Date:  2006-11-08

6.  Analysis of Fcgamma receptor haplotypes in rheumatoid arthritis: FCGR3A remains a major susceptibility gene at this locus, with an additional contribution from FCGR3B.

Authors:  Ann W Morgan; Jennifer H Barrett; Bridget Griffiths; Deepak Subramanian; Jim I Robinson; Viki H Keyte; Manir Ali; Elizabeth A Jones; Robert W Old; Frederique Ponchel; Arthur W Boylston; R Deva Situnayake; Alexander F Markham; Paul Emery; John D Isaacs
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

7.  Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients.

Authors:  Gianmaria Miolo; Elena Muraro; Debora Martorelli; Davide Lombardi; Simona Scalone; Simon Spazzapan; Samuele Massarut; Tiziana Perin; Elda Viel; Elisa Comaro; Renato Talamini; Ettore Bidoli; Elisa Turchet; Diana Crivellari; Riccardo Dolcetti
Journal:  BMC Cancer       Date:  2014-12-15       Impact factor: 4.430

8.  Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies.

Authors:  E C Pietsch; J Dong; R Cardoso; X Zhang; D Chin; R Hawkins; T Dinh; M Zhou; B Strake; P-H Feng; M Rocca; C Dos Santos; X Shan; G Danet-Desnoyers; F Shi; E Kaiser; H J Millar; S Fenton; R Swanson; J A Nemeth; R M Attar
Journal:  Blood Cancer J       Date:  2017-02-24       Impact factor: 11.037

Review 9.  Functional Assays in the Diagnosis of Heparin-Induced Thrombocytopenia: A Review.

Authors:  Valentine Minet; Jean-Michel Dogné; François Mullier
Journal:  Molecules       Date:  2017-04-11       Impact factor: 4.411

Review 10.  The Human FcγRII (CD32) Family of Leukocyte FcR in Health and Disease.

Authors:  Jessica C Anania; Alicia M Chenoweth; Bruce D Wines; P Mark Hogarth
Journal:  Front Immunol       Date:  2019-03-19       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.